BMRN
Biomarin Pharmaceutical Inc
A biotechnology company focused on rare genetic diseases, BioMarin makes enzyme-replacement and gene therapies—including VOXZOGO, the first drug approved to treat achondroplasia (dwarfism) in children—alongside treatments like VIMIZIM and NAGLAZYME used by patients with rare metabolic disorders. Founded in 1997 in Marin County, California, the company's name blends "bio" for biotechnology with "Marin," the county where it got its start. Its early founders deliberately took on rare diseases that bigger drugmakers ignored, and the company has since grown into one of the world's largest rare-disease biotechs.
CUSIP: 09061G101HealthcareUS4 holders
Recent Activity
2026Q2
3 buys1 sell
+68.0K shares(+32.9%)
+68.0K shares(+32.9%)
+283.2K shares(+1.9%)
Dodge & CoxADD
+283.2K shares(+1.9%)
-465 shares(-0.6%)
-465 shares(-0.6%)
+554.5K shares(+7.9%)
+554.5K shares(+7.9%)
2026Q1
2 buys2 sells
-23.1K shares(-10.0%)
-23.1K shares(-10.0%)
-10.6K shares(-0.1%)
Dodge & CoxTRIM
-10.6K shares(-0.1%)
+78.2K shares
+78.2K shares
+1.03M shares(+17.0%)
+1.03M shares(+17.0%)
Loading more activity...